Profile of:

Adrian Ciurea


Adrian Ciurea (Prof. Dr. med.) is a rheumatologist and clinical research scientist in Switzerland. He is deputy head of the Department of Rheumatology at the University Hospital in Zurich and head of the outpatient clinics. Since 2012 he is the chairman of the scientific committee of the Swiss Clinical Quality Management (SCQM) Axial Spondyloarthritis Cohort. He is also President of the Swiss Bechterew Foundation.

Full name: Adrian Ciurea

Current country: Switzerland

Membership level: Full

Type of membership: Member

Number of publications: 58

Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/35110365/

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update (2022)
https://pubmed.ncbi.nlm.nih.gov/36270658/

Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry (2022)
https://pubmed.ncbi.nlm.nih.gov/36270744/

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/35323903/

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration (2022)
https://pubmed.ncbi.nlm.nih.gov/35985172/

Lessons learned from a pilot implementation of physical activity recommendations in axial spondyloarthritis exercise group therapy (2022)
https://pubmed.ncbi.nlm.nih.gov/35034652/

Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseases (2022)
https://pubmed.ncbi.nlm.nih.gov/35820737/

Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls (2022)
https://pubmed.ncbi.nlm.nih.gov/35810064/

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course (2022)
https://pubmed.ncbi.nlm.nih.gov/35664993/

One-third of European axial spondyloarthritis patients reach pain”remission” with routine care TNF-inhibitor treatment (2022)
https://pubmed.ncbi.nlm.nih.gov/36455943/

HLA‑B27 as a predictor of efectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry (2022)
https://pubmed.ncbi.nlm.nih.gov/36574181/

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. (2022)
https://pubmed.ncbi.nlm.nih.gov/36311791/

Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors (2021)
https://pubmed.ncbi.nlm.nih.gov/34107999/

European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response (2021)
https://pubmed.ncbi.nlm.nih.gov/34940840/

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort (2021)
https://pubmed.ncbi.nlm.nih.gov/32963052/

Reliability of an adapted core strength endurance test battery in individuals with axial spondylarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/32959189/

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration (2021)
https://pubmed.ncbi.nlm.nih.gov/34083206/

Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction (2021)
https://pubmed.ncbi.nlm.nih.gov/33811177/

Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort (2020)
https://pubmed.ncbi.nlm.nih.gov/33036663/

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort (2020)
https://pubmed.ncbi.nlm.nih.gov/32581090/

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort (2020)
https://pubmed.ncbi.nlm.nih.gov/32196530/

Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31960053/

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration (2020)
https://pubmed.ncbi.nlm.nih.gov/32950963/

Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study (2020)
https://pubmed.ncbi.nlm.nih.gov/32712263/

Ossification of the ligamentum flavum (2020)
https://pubmed.ncbi.nlm.nih.gov/31819998/

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31145730/

Barriers and Facilitators of Vigorous Cardiorespiratory Training in Axial Spondyloarthritis: Surveys Among Patients, Physiotherapists, and Rheumatologists (2019)
https://pubmed.ncbi.nlm.nih.gov/30004189/

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts (2019)
https://pubmed.ncbi.nlm.nih.gov/31362994/

Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration (2019)
https://pubmed.ncbi.nlm.nih.gov/31431486/

The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort (2019)
https://pubmed.ncbi.nlm.nih.gov/31039159/

Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study (2019)
https://pubmed.ncbi.nlm.nih.gov/30877773/

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort (2018)
https://pubmed.ncbi.nlm.nih.gov/29449504/

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort (2018)
https://pubmed.ncbi.nlm.nih.gov/28939631/

Early undifferentiated arthritis (2018)
https://pubmed.ncbi.nlm.nih.gov/29468290/

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28724442/

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28087505/

The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance (2017)
https://pubmed.ncbi.nlm.nih.gov/28701277/

The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis (2016)
https://pubmed.ncbi.nlm.nih.gov/27015429/

Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis (2016)
https://pubmed.ncbi.nlm.nih.gov/25667205/

Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort (2016)
https://pubmed.ncbi.nlm.nih.gov/27000865/

HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats (2015)
https://pubmed.ncbi.nlm.nih.gov/26125554/

Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort (2015)
https://pubmed.ncbi.nlm.nih.gov/25362654/

Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria (2015)
https://pubmed.ncbi.nlm.nih.gov/25070142/

Correlation of findings in clinical and high resolution ultrasonography examinations of the painful shoulder (2015)
https://pubmed.ncbi.nlm.nih.gov/26674725/

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis (2015)
https://pubmed.ncbi.nlm.nih.gov/26699169/

Age at symptom onset in ankylosing spondylitis: is there a gender difference? (2014)
https://pubmed.ncbi.nlm.nih.gov/25104774/

Gender differences in axial spondyloarthritis (2014)
https://www.wjgnet.com/2220-3214/full/v4/i3/35.htm

Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort (2013)
https://pubmed.ncbi.nlm.nih.gov/23983141/

Effect of cardiovascular training on fitness and perceived disease activity in people with ankylosing spondylitis (2013)
https://pubmed.ncbi.nlm.nih.gov/23836515/

BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment (2013)
https://pubmed.ncbi.nlm.nih.gov/23165181/

Smoking and spondyloarthritis. (2013)
https://pubmed.ncbi.nlm.nih.gov/23238005/

High bone turnover assessed by 18F-fluoride PET/CT in the spine and sacroiliac joints of patients with ankylosing spondylitis: comparison with inflammatory lesions detected by whole body MRI (2012)
https://pubmed.ncbi.nlm.nih.gov/22788874/

18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis (2010)
https://pubmed.ncbi.nlm.nih.gov/20505935/

Public versus personal serotypes of a viral quasispecies (2003)
https://pubmed.ncbi.nlm.nih.gov/12730366/

CD4+ T-cell-epitope escape mutant virus selected in vivo (2001)
https://pubmed.ncbi.nlm.nih.gov/11433343/

Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants (2001)
https://pubmed.ncbi.nlm.nih.gov/11157050/

Viral persistence in vivo through selection of neutralizing antibody-escape variants (2000)
https://pubmed.ncbi.nlm.nih.gov/10688894/

Viral escape and the failure of cellular immune responses (2000)
https://pubmed.ncbi.nlm.nih.gov/11032545/